Switch theme
Sign up to access all valuation multiples
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
2015
205
LTM Revenue $83.2M
LTM EBITDA -$28.8M
$118M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Akoya Biosciences has a last 12-month revenue (LTM) of $83.2M and a last 12-month EBITDA of -$28.8M.
In the most recent fiscal year, Akoya Biosciences achieved revenue of $81.7M and an EBITDA of -$37.1M.
Akoya Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Akoya Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $83.2M | XXX | $81.7M | XXX | XXX | XXX |
| Gross Profit | $49.8M | XXX | $47.9M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | -$28.8M | XXX | -$37.1M | XXX | XXX | XXX |
| EBITDA Margin | -35% | XXX | -45% | XXX | XXX | XXX |
| EBIT | -$40.4M | XXX | -$41.2M | XXX | XXX | XXX |
| EBIT Margin | -49% | XXX | -50% | XXX | XXX | XXX |
| Net Profit | -$49.9M | XXX | -$55.4M | XXX | XXX | XXX |
| Net Margin | -60% | XXX | -68% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $64.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Akoya Biosciences's stock price is $1.
Akoya Biosciences has current market cap of $61.8M, and EV of $118M.
See Akoya Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $118M | $61.8M | XXX | XXX | XXX | XXX | $-0.98 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Akoya Biosciences has market cap of $61.8M and EV of $118M.
Akoya Biosciences's trades at 1.4x EV/Revenue multiple, and -3.2x EV/EBITDA.
Equity research analysts estimate Akoya Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Akoya Biosciences has a P/E ratio of -1.2x.
See valuation multiples for Akoya Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $61.8M | XXX | $61.8M | XXX | XXX | XXX |
| EV (current) | $118M | XXX | $118M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | -4.1x | XXX | -3.2x | XXX | XXX | XXX |
| EV/EBIT | -2.9x | XXX | -2.9x | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.2x | XXX | -1.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAkoya Biosciences's last 12 month revenue growth is 7%
Akoya Biosciences's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Akoya Biosciences's rule of 40 is -40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Akoya Biosciences's rule of X is -17% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Akoya Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | -35% | XXX | -45% | XXX | XXX | XXX |
| EBITDA Growth | -14% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -40% | XXX | -38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -17% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 109% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akoya Biosciences acquired XXX companies to date.
Last acquisition by Akoya Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Akoya Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Akoya Biosciences founded? | Akoya Biosciences was founded in 2015. |
| Where is Akoya Biosciences headquartered? | Akoya Biosciences is headquartered in United States of America. |
| How many employees does Akoya Biosciences have? | As of today, Akoya Biosciences has 205 employees. |
| Who is the CEO of Akoya Biosciences? | Akoya Biosciences's CEO is Mr. Brian McKelligon. |
| Is Akoya Biosciences publicy listed? | Yes, Akoya Biosciences is a public company listed on NAS. |
| What is the stock symbol of Akoya Biosciences? | Akoya Biosciences trades under AKYA ticker. |
| When did Akoya Biosciences go public? | Akoya Biosciences went public in 2021. |
| Who are competitors of Akoya Biosciences? | Similar companies to Akoya Biosciences include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Akoya Biosciences? | Akoya Biosciences's current market cap is $61.8M |
| What is the current revenue of Akoya Biosciences? | Akoya Biosciences's last 12 months revenue is $83.2M. |
| What is the current revenue growth of Akoya Biosciences? | Akoya Biosciences revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Akoya Biosciences? | Current revenue multiple of Akoya Biosciences is 1.4x. |
| Is Akoya Biosciences profitable? | Yes, Akoya Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Akoya Biosciences? | Akoya Biosciences's last 12 months EBITDA is -$28.8M. |
| What is Akoya Biosciences's EBITDA margin? | Akoya Biosciences's last 12 months EBITDA margin is -35%. |
| What is the current EV/EBITDA multiple of Akoya Biosciences? | Current EBITDA multiple of Akoya Biosciences is -4.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
